Retatrutide + Cagrilintide Blend

Global Peptide Sciences supplies the retatrutide and cagrilintide blend to laboratories across Australia, supporting studies into multi-pathway metabolic signalling, appetite regulation and energy balance research.

This blend combines two independently investigated compounds. Retatrutide is a triple receptor agonist acting on the GLP-1, GIP and glucagon receptors, while cagrilintide is a long-acting amylin analogue engineered to activate amylin and calcitonin receptor pathways. Pairing them gives researchers a single material for exploring how incretin, glucagon and amylin signalling systems interact, rather than sourcing and combining two separate compounds independently.

Each batch is produced under controlled manufacturing conditions and undergoes independent laboratory verification, supporting consistent, repeatable results across analytical testing. A Certificate of Analysis is available on request for every order.

What Is the Retatrutide and Cagrilintide Blend?

Many researchers ask what this blend is and why these two particular compounds have been paired together for research use.

Retatrutide and cagrilintide act on genuinely distinct receptor families. Retatrutide engages the incretin and glucagon receptor systems associated with appetite signalling and energy expenditure, while cagrilintide works through amylin receptor subtypes and the calcitonin receptor, a pathway linked to satiety, gastric emptying and separate neural appetite circuits. It is worth noting that while each compound individually has an established body of trial data, and cagrilintide has completed trials in combination with a GLP-1 agonist, the specific pairing of retatrutide with cagrilintide has not itself been the subject of published combination trials. Researchers working with this blend are therefore exploring a mechanistic hypothesis built on each compound’s individual pathway data, rather than combination-specific clinical results.

Cagrilintide and Retatrutide Blend Benefits in Research

Within controlled laboratory settings, research connected to this cagrilintide retatrutide blend commonly looks at areas such as:

• Combined incretin, glucagon and amylin receptor signalling research
• Appetite and satiety pathway studies
• Energy balance and gastric emptying research
• Comparative multi-pathway metabolic modelling

These points reflect laboratory observation only and are not intended as claims about therapeutic or weight-related outcomes.

Research Areas of Interest

• Studies into amylin receptor subtype signalling (AMY1R, AMY2R, AMY3R)
• Investigation of combined incretin and amylin pathway interaction
• Comparative research against single-pathway receptor agonists
• Energy expenditure and appetite circuit modelling

Product Information

• Compound: Retatrutide + Cagrilintide Blend
• Classification: Combined triple receptor agonist (GLP-1, GIP, glucagon) and amylin receptor agonist
• Composition: Retatrutide 12.5 mg, Cagrilintide 2.5 mg per vial
• Form: Lyophilised powder blend
• Purity level: 99% or above (HPLC / MS verified)
• Testing: Independent third-party laboratory verification, CoA available on request
• Storage: Store at -20°C

Retatrutide + Cagrilintide Blend Reconstitution

Researchers reconstituting this retatrutide and cagrilintide blend for laboratory use typically follow standard laboratory protocols for combining lyophilised peptides with an appropriate sterile diluent prior to further analytical handling. Global Peptide Sciences does not provide reconstitution instructions intended for self-administration, and all reconstitution should be carried out in accordance with your own laboratory’s established procedures and safety documentation.

Why Researchers Study This Blend

Laboratories examining multi-pathway metabolic signalling reference this blend because it allows simultaneous investigation of incretin and glucagon receptor engagement alongside amylin receptor engagement within a single research material. Both individual compounds remain investigational. Retatrutide is currently in Phase 3 clinical development, and cagrilintide has completed Phase 3 trials both alone and in fixed-dose combination with a GLP-1 agonist, though it remains unapproved as a standalone medicine. Neither compound is included on the Australian Register of Therapeutic Goods, and any interaction specific to retatrutide with cagrilintide together should be treated as a research hypothesis rather than an established finding.

Researchers comparing options across related metabolic compounds can explore the full weight management research category for additional research materials.

Buy the Retatrutide and Cagrilintide Blend in Australia

Researchers looking for this cagrilintide and retatrutide combination can access verified, batch-tested material through Global Peptide Sciences, with independent Certificates of Analysis available for every order.

Laboratories comparing retatrutide with cagrilintide as separate compounds against this pre-combined blend, or asking about sourcing cagrilintide with retatrutide for a single study design, can rely on a consistent supply chain backed by HPLC and LC-MS verification. Researchers can review product-specific documentation directly before finalising an order.

Global Peptide Sciences offers consistent quality control at every stage of supply, and researchers can browse the full catalogue to view other research compounds available alongside this blend.

Research Use Only

This compound is supplied strictly for laboratory research purposes and is not approved for human consumption or therapeutic use.